Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

DRG International, Inc.

DRG International, a global innovator of high-quality medical diagnostics and equipment, provides the medical and res... read more Featured Products: More products

Download Mobile App





DRG Instruments Demonstrates DRG:HYBRID-XL Fully Automated Lab Analyzer

By LabMedica International staff writers
Posted on 21 Nov 2019
DRG Instruments GmbH (Marburg, Germany) demonstrated its fully automated random access analyzer, DRG:HYBRiD-XL, along with its newest ELISAs, at this year's MEDICA, the world's largest annual medical technology trade fair, that took place from 18-21 November in Düsseldorf, Germany. More...
MEDICA provides the medical device industry with a central market for innovative products and systems that result in an important contribution to the efficiency and quality of patient care. The combination of product shows with international congresses, forums, as well as expert workshops, and the exchange of professional views make MEDICA a meeting point for international professionals from various fields in the medical sector.

DRG Instruments specializes in the development and production of innovative ELISAs and Chemiluminescent assays, both for routine and research applications, in the fields of diabetes diagnosis, endocrinology, prenatal/neonatal supervision, thyroid function and many more. Recently, DRG Instruments developed the world’s first nonradioactive immunoassays for the determination of active Renin and PLGF, as well as a complete panel of sensitive assays for the quantitative determination of saliva steroids. In the last five years, DRG Instruments has developed its own tumor marker panel and a broad range of ELISAS in the field of infectious diseases, including the world’s first assay for the qualitative detection of human Fasciola IgG.

At the MEDICA 2019 International Trade Fair, DRG demonstrated DRG:HYBRiD-XL, its fully automated, continuous access analyzer that allows the simultaneous measurement of immunoassays and clinical chemistry parameters, including turbidimetric tests, in one sample. It allows medical practitioners to carry out up to 40 tests of different types or 40 times of the same test, or up to 20-patient samples over a wide range of pre-packaged tests to serve different specialties.

Additionally, DRG presented several new DRG ELISAs, including Bordetella pertussis Toxin IgA/IgG (quantitative), Aspergillus fumigatus IgG/IgM and Bartonella Ab, at the event. The company also displayed its new and optimized SALIVA ELISAs: Unique Salivary Hepcidin and optimized Salivary Estradiol. The company’s saliva diagnostics products offer several benefits such as non-invasive sampling, measurement of the free (unbounded) fraction of steroids, and much higher diagnostic relevance with reproducible and reliable results, compared to serum analytics.

Related Links:
DRG Instruments GmbH


New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.